NCT04511416 · Phase 3 · ACTIVE NOT RECRUITING
Preventing Cognitive Decline with Metformin
This trial tests whether metformin, a common diabetes drug, can slow cognitive decline in overweight or obese adults with mild cognitive impairment who do not have diabetes. Researchers will track thinking tests and brain imaging over 3 years. It is a Phase 3 trial, a larger step testing whether it works and is safe, not yet proven or approved for this use.
You may qualify if
- overweight or obese (body mass index >25.0 kg/m2, waist: women>80 cm, men>94cm;
- Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;
- Fasting blood glucose \<7.0 mmol/L and HbA1c \<6.5%;
- Able to undertake neurocognitive testing in English.
- Not participating in another trial of drugs or lifestyle modification to reduce cognitive decline.
You're excluded if
- Life-threatening illnesses to preclude participation in a 3-year study;
- Contraindications to the use of metformin (severe heart failure or eGFR \<40).
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-10-02